FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893199708> ?p ?o ?g. }

• W2893199708 endingPage "913" @default.
• W2893199708 startingPage "908" @default.
• W2893199708 abstract "To determine frequency and syndrome specificity of novel and known nervous system (NS)-directed antibodies in a large, unbiased cohort of SLE patients in the Swiss SLE Cohort Study.This retrospective pilot study included 174 patients in a cross-sectional and 102 in a longitudinal study. Antibodies against 12 NS antigens [myelin oligodendrocyte glycoprotein (MOG), neurofascin 186 (NF186), aquaporin-4 (AQP4), N-methyl-D-aspartate receptor (subunit NR1) (NMDAR-NR1), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (subunits 1 and 2) (AMPAR1/2), gamma-aminobutyric acid B receptor (subunits B1 and B2) (GABABR1/2), glutamate decarboxylase 65 (GAD65), glycine receptor (GlyR), contactin-associated protein-like 2 (CASPR2), leucine-rich glioma-inactivated 1 (LGI1), metabotropic glutamate receptor 5 (mGluR5) and dipeptidyl-peptidase-like protein 6 (DPPX)] were screened with validated cell-based assays and correlated with clinical and diagnostic findings.Twenty-three of one hundred and seventy-four (13.2%) patients harboured antibodies against MOG (n = 14), NF186 (n = 6), GAD65 (n = 2), AQP4 and GlyR (n = 1). Anti-MOG antibodies were most frequently found in the cohort (8%). Thirteen of the anti-NS antibody-positive patients showed clinical symptoms of NS involvement, a subgroup of which (n = 8) resembled the syndrome associated with the antibody. Nine patients harboured antibodies without neurological symptoms and one patient was lost to follow-up. The frequency of NPSLE was significantly higher in the anti-NS antibody-positive patients (13/23, 56.5%: MOG 6/14, 42.9%; NF186 5/6, 83.3%; GAD65 2/2, 100%; AQP4/GlyR 0/1, 0%) compared with the antibody-negative cohort (21/151, 13.9%) (chi-square test, P < 0.0001).Anti-NS antibodies, most prevalently anti-MOG antibodies, are significantly associated with NPSLE and manifest with the distinct neurological syndrome associated with the antibody in a subgroup. Follow-up studies in large, independent cohorts will reveal whether these anti-NS antibodies could serve as a diagnostic and prognostic biomarker for NPSLE and enable tailored treatment decisions in this challenging and diverse patient cohort." @default.
• W2893199708 created "2018-10-05" @default.
• W2893199708 creator A5023854384 @default.
• W2893199708 creator A5024962191 @default.
• W2893199708 creator A5026513501 @default.
• W2893199708 creator A5037871954 @default.
• W2893199708 creator A5045305298 @default.
• W2893199708 creator A5045808892 @default.
• W2893199708 creator A5046877731 @default.
• W2893199708 creator A5054874316 @default.
• W2893199708 creator A5061159661 @default.
• W2893199708 creator A5071466585 @default.
• W2893199708 creator A5076869396 @default.
• W2893199708 creator A5082565601 @default.
• W2893199708 creator A5083827025 @default.
• W2893199708 creator A5090330730 @default.
• W2893199708 date "2018-09-27" @default.
• W2893199708 modified "2023-10-06" @default.
• W2893199708 title "Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus" @default.
• W2893199708 cites W1943450887 @default.
• W2893199708 cites W1993823752 @default.
• W2893199708 cites W2034772063 @default.
• W2893199708 cites W2048956613 @default.
• W2893199708 cites W2049923210 @default.
• W2893199708 cites W2069255656 @default.
• W2893199708 cites W2070527591 @default.
• W2893199708 cites W2078610240 @default.
• W2893199708 cites W2094929674 @default.
• W2893199708 cites W2114690058 @default.
• W2893199708 cites W2115561534 @default.
• W2893199708 cites W2130494087 @default.
• W2893199708 cites W2137679015 @default.
• W2893199708 cites W2155551728 @default.
• W2893199708 cites W2155599479 @default.
• W2893199708 cites W2185385331 @default.
• W2893199708 cites W2331045106 @default.
• W2893199708 cites W2561536790 @default.
• W2893199708 cites W2766718777 @default.
• W2893199708 doi "https://doi.org/10.1093/rheumatology/key282" @default.
• W2893199708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30265368" @default.
• W2893199708 hasPublicationYear "2018" @default.
• W2893199708 type Work @default.
• W2893199708 sameAs 2893199708 @default.
• W2893199708 citedByCount "16" @default.
• W2893199708 countsByYear W28931997082018 @default.
• W2893199708 countsByYear W28931997082019 @default.
• W2893199708 countsByYear W28931997082020 @default.
• W2893199708 countsByYear W28931997082021 @default.
• W2893199708 countsByYear W28931997082022 @default.
• W2893199708 countsByYear W28931997082023 @default.
• W2893199708 crossrefType "journal-article" @default.
• W2893199708 hasAuthorship W2893199708A5023854384 @default.
• W2893199708 hasAuthorship W2893199708A5024962191 @default.
• W2893199708 hasAuthorship W2893199708A5026513501 @default.
• W2893199708 hasAuthorship W2893199708A5037871954 @default.
• W2893199708 hasAuthorship W2893199708A5045305298 @default.
• W2893199708 hasAuthorship W2893199708A5045808892 @default.
• W2893199708 hasAuthorship W2893199708A5046877731 @default.
• W2893199708 hasAuthorship W2893199708A5054874316 @default.
• W2893199708 hasAuthorship W2893199708A5061159661 @default.
• W2893199708 hasAuthorship W2893199708A5071466585 @default.
• W2893199708 hasAuthorship W2893199708A5076869396 @default.
• W2893199708 hasAuthorship W2893199708A5082565601 @default.
• W2893199708 hasAuthorship W2893199708A5083827025 @default.
• W2893199708 hasAuthorship W2893199708A5090330730 @default.
• W2893199708 hasConcept C126322002 @default.
• W2893199708 hasConcept C147483822 @default.
• W2893199708 hasConcept C159654299 @default.
• W2893199708 hasConcept C163764329 @default.
• W2893199708 hasConcept C181199279 @default.
• W2893199708 hasConcept C203014093 @default.
• W2893199708 hasConcept C2778609137 @default.
• W2893199708 hasConcept C2779357208 @default.
• W2893199708 hasConcept C2781137167 @default.
• W2893199708 hasConcept C529278444 @default.
• W2893199708 hasConcept C55493867 @default.
• W2893199708 hasConcept C71924100 @default.
• W2893199708 hasConcept C86803240 @default.
• W2893199708 hasConcept C90924648 @default.
• W2893199708 hasConcept C9497952 @default.
• W2893199708 hasConceptScore W2893199708C126322002 @default.
• W2893199708 hasConceptScore W2893199708C147483822 @default.
• W2893199708 hasConceptScore W2893199708C159654299 @default.
• W2893199708 hasConceptScore W2893199708C163764329 @default.
• W2893199708 hasConceptScore W2893199708C181199279 @default.
• W2893199708 hasConceptScore W2893199708C203014093 @default.
• W2893199708 hasConceptScore W2893199708C2778609137 @default.
• W2893199708 hasConceptScore W2893199708C2779357208 @default.
• W2893199708 hasConceptScore W2893199708C2781137167 @default.
• W2893199708 hasConceptScore W2893199708C529278444 @default.
• W2893199708 hasConceptScore W2893199708C55493867 @default.
• W2893199708 hasConceptScore W2893199708C71924100 @default.
• W2893199708 hasConceptScore W2893199708C86803240 @default.
• W2893199708 hasConceptScore W2893199708C90924648 @default.
• W2893199708 hasConceptScore W2893199708C9497952 @default.
• W2893199708 hasFunder F4320321862 @default.
• W2893199708 hasIssue "5" @default.
• W2893199708 hasLocation W28931997081 @default.

• next